News

Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
In addition, in the second half of 2025, Verve remains on track to report the final data for the dose escalation portion of the Heart-2 clinical trial, deliver the opt-in package for the PCSK9 program ...
FDA reverses RTO mandate and restores telework for key staff
Whatever the reasoning behind the telework shift, former federal officials say it’s a sign that recently confirmed FDA ...